Hormone Receptor Positive Tumor Recruiting Phase 2 Trials for Tamoxifen (DB00675)

IndicationStatusPhase
DBCOND0075370 (Hormone Receptor Positive Tumor)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03906669A Window of Opportunity Study of Pre-operative Endocrine Therapy With and Without Prometrium in Postmenopausal Women With Early Stage Breast Hormone Receptor Positive (HR+) Human Epidermal Receptor 2 Negative (HER2-) Breast Cancer.Treatment
NCT02592083Neoadjuvant Response-guided Treatment of Slowly Proliferating Hormone Receptor Positive TumorsTreatment